Capha Pharmaceuticals Inc.

FPSUF

CA13962W1086

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:51:43 2023-02-27 EST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

05-30	Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-26	Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 30, 2024 at 09:21 am

Capha Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was CAD 0.015268 million compared to CAD 0.017634 million a year ago.

Latest news about Capha Pharmaceuticals Inc.

Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Capha Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	23-04-25	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-27	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
Capha Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-29	CI
Mill City Gold Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2018	18-11-28	CI

Chart Capha Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Capha Pharmaceuticals Inc. is a Canada-based company. The Company is engaged in exploring various opportunities in the medical technology space.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CAPHA PHARMACEUTICALS INC.	-.--%	64
ELI LILLY AND COMPANY	+55.55%	823B
NOVO NORDISK A/S	+42.31%	641B
JOHNSON & JOHNSON	-6.83%	352B
MERCK & CO., INC.	+17.15%	324B
ABBVIE INC.	+7.09%	301B
ASTRAZENECA PLC	+14.02%	241B
ROCHE HOLDING AG	+1.64%	223B
NOVARTIS AG	+13.66%	218B
AMGEN INC.	+7.87%	167B